Author:
Annette Schaub,Stephan Goerigk,Mueser Kim T.,Martin Hautzinger,Elisabeth Roth,Ulrich Goldmann,Marketa Charypar,Rolf Engel,Hans-Jürgen Möller,Peter Falkai
Abstract
AbstractNeuropsychological functioning turns out to be a rate-limiting factor in psychiatry. However, little is known when comparing neuropsychological and psychosocial functioning in inpatients with schizophrenia or severe depression in their treatment pathways including add-on psychoeducation or the latter combined with cognitive behavioral therapy up to 2-year follow-up. To evaluate this question, we investigated these variables in two randomised controlled trials including 196 patients with DSM-IV schizophrenia and 177 patients with major depression. Outcome measures were assessed in the hospital at pre- and posttreatment and following discharge until 2-year follow-up. We focused on neuropsychological and psychosocial functioning regarding its differences and changes over time in data of two pooled trials. There were significant time effects indicating gains in knowledge about the illness, short and medium-term memory (VLMT) and psychosocial functioning (GAF), however, the latter was the only variable showing a time x study/diagnosis interaction effect at 2-year follow-up, showing significant better outcome in depression compared to schizophrenia. Moderator analysis showed no changes in psychosocial and neuropsychological functioning in schizophrenia and in affective disorders due to age, duration of illness or sex. Looking at the rehospitalisation rates there were no significant differences between both disorders. Both groups treated with psychoeducation or a combination of psychoeducation and CBT improved in neuropsychological and psychosocial functioning as well as knowledge about the illness at 2-year follow-up, however, patients with major depression showed greater gains in psychosocial functioning compared to patients with schizophrenia. Possible implications of these findings were discussed.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Biological Psychiatry,Psychiatry and Mental health,General Medicine
Reference62 articles.
1. Falkai P, Schennach-Wolf R, Lincoln T, Schaub A, Hasan A (2017). Schizophrene Psychosen, Kap. 65; Teil VII, Schizophrenie ähnliche Störungen und nichtorganische Wahnerkrankungen. In: Möller H-J, Laux G, Kapfhammer H-P (Hrsg.): Psychiatrie, Psychosomatik, Psychotherapie. Band 3 Spezielle Psychiatrie 1 (5.Aufl.) Berlin, Springer, Kapitel 65 Seiten 1583–1674. ISBN: 978-3-662-49294–2, ISBN; 978-3-662-49295-6. doi:10.1007/978-3-642-45028-0_64-1
2. Mathers C (2004) The global burden of disease: 2004 update
3. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, Rush AJ, Walters EE, Wang PS (2003) The epidemiology of major depressive disorder: results from the National comorbidity survey replication (NCS-R). JAMA 289:3095–3105
4. Jablensky A, Sartorius N, Ernberg G et al (1992) Schizophrenia: manifestations, incidence and course in different cultures. A world health organization ten-country study. Psychol Med (Monograph Suppl 20). Cambridge University Press, Cambridge
5. Rink L, Pagel T, Franklin J, Baethge C (2016) Characteristics and heterogeneity of schizoaffective disorder compared with unipolar depression and schizophrenia—a systematic literature review and meta-analysis. J Affect Disord 191:8–14
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献